Fusion of the new coronavirus (SARS-CoV-2) in human cells: the role of Angiotensin-Converting Enzyme 2 (ECA2) and Transmembrane Serine Protease 2 (TMPRSS2)
There are several types of coronavirus, however it is known that three types are responsible for severe respiratory infection in humans: SARS-CoV (SARS), Mers-CoV (MERS) and the new SARS-CoV-2. Transmission occurs through contamination of salivary fluids, particles retained in the air by sneezing or coughing, close contact with contaminated people and surfaces. And the first symptoms occur between 2 to 14 days, called the viral incubation period. Because it is a new pathology, severe symptoms and abnormalities defy science. There are several pharmacological possibilities in testing phases. It is relevant to unveil studies on Angiotensin-Converting Enzyme 2 (ECA2) and Transmembrane Protease, serine 2 (TMPRSS2) in SARS-CoV-2, enzymatic targets with pharmacological perspectives for the treatment of COVID-19. Based on this premise, pharmaceutical products targeting the inhibition of ECA2 and TMPRSS2 have promising expectations in the treatment of SARS-CoV-2. After all, the inhibition of ACE2, an enzyme located in the main organs where the disease proliferates, has the potential to decrease the release of pro-inflammatory cytokines. While inhibition of TMPRSS2 would prevent the virus from entering human cells at the level of the upper respiratory tract.
Copyright (c) 2020 InterAmerican Journal of Medicine and Health
This work is licensed under a Creative Commons Attribution 4.0 International License.